BIOMAT Database Logo BIOMAT Database Logo

Dibenzoxepin derivatives: thromboxane A2 synthase inhibition and thromboxane A2 receptor antagonism combined in one molecule. 1993

E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.

A new series of 6,11-dihydrodibenz[b,e]oxepin derivatives exerting both thromboxane synthase inhibitory (TXS-I) and thromboxane receptor antagonist (TXRA) activities is described. (-)-11-[(3-Pyridylmethyl)thio]-6,11-dihydrodibenz[b,e]oxepin -2- carboxylic acid [(-)-3] and (E)-11-[2-(3-pyridyl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin+ ++-2- carboxylic acid methanesulfonate (11E) exhibited potent inhibitory effects on bovine platelet thromboxane synthase with IC50 values of 4.0 and 14 nM, respectively, and these derivatives also antagonized guinea pig platelet TXA2/PGH2 receptors with Ki values of 85 and 180 nM, respectively. Compound 11E exhibited the dual inhibitory activity in ex vivo experiments and demonstrated a significant protective effect in a rat acute renal failure model.

UI MeSH Term Description Entries
D008297 Male Males
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D003990 Dibenzoxepins
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013930 Thromboxane-A Synthase An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5. Thromboxane Synthetase,Thromboxane A Synthase,Thromboxane A2 Synthetase,A2 Synthetase, Thromboxane,Synthase, Thromboxane A,Synthase, Thromboxane-A,Synthetase, Thromboxane,Synthetase, Thromboxane A2

Related Publications

E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
August 1993, Hypertension (Dallas, Tex. : 1979),
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
January 1989, Progress in clinical and biological research,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
April 1999, Journal of medicinal chemistry,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
June 1991, Journal of medicinal chemistry,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
February 1989, Thrombosis and haemostasis,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Thromboxane receptor antagonism and synthase inhibition in cerebral ischemia.
March 1993, Prostaglandins, leukotrienes, and essential fatty acids,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
February 1989, Thrombosis and haemostasis,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.
November 1992, Journal of medicinal chemistry,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
November 1987, The Journal of clinical investigation,
E Ohshima, and H Sato, and H Obase, and I Miki, and A Ishii, and M Kawakage, and S Shirakura, and A Karasawa, and K Kubo
Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.
October 2000, Acta crystallographica. Section C, Crystal structure communications,
Copied contents to your clipboard!